INO80 governs superenhancer-mediated oncogenic transcription and tumor growth in melanoma

Genes and Development

Volumn 30, Issue 12, 2016, Pages 1440-1453

  Zhou, Bingying ^a,b,c   Wang, Li ^a,d   Zhang, Shu ^e   Bennett, Brian D ^d   He, Fan ^f   Zhang, Yan ^f   Xiong, Chengliang ^f   Han, Leng ^g   Diao, Lixia ^h   Li, Pishun ^d   Fargo, David C ^d   Cox, Adrienne D ^b,c   Hu, Guang ^d  

^a FUWAI HOSPITAL   (China)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^e CHINESE PLA GENERAL HOSPITAL   (China)

^f HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^g UNIVERSITY OF TEXAS   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chromatin remodeler; INO80; Oncogenic transcription; Superenhancer

Indexed keywords

B RAF KINASE; EPHRIN RECEPTOR A2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; INO80 PROTEIN; MESSENGER RNA; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OSTEONECTIN; PROTEIN SWI; TRAMETINIB; TRANSCRIPTION FACTOR SNF; TRANSCRIPTION FACTOR SOX9; TUMOR PROMOTER; UNCLASSIFIED DRUG; VEMURAFENIB; CELL CYCLE PROTEIN; INO80B PROTEIN, HUMAN; MED1 PROTEIN, HUMAN; NUCLEAR PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR BINDING PROTEIN; PROTEIN BINDING; TRANSCRIPTION FACTOR;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; CONTROLLED STUDY; DOWN REGULATION; ENHANCER REGION; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MELANOCYTE; MELANOMA; MELANOMA CELL; MOUSE; NEVUS; NONHUMAN; ONCOGENE N RAS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; SUPERENHANCER; TRANSCRIPTION INITIATION SITE; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; XENOGRAFT;

ANIMALS; CARCINOGENESIS; CELL CYCLE PROTEINS; CELL PROLIFERATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; ENHANCER ELEMENTS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HETEROGRAFTS; HUMANS; MEDIATOR COMPLEX SUBUNIT 1; MELANOCYTES; MELANOMA; MICE; NUCLEAR PROTEINS; PROTEIN BINDING; TRANSCRIPTION FACTORS;

EID: 84975717751     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.277178.115     Document Type: Article

References (41)

1. Affer M, Chesi M, Chen WD, Keats JJ, Demchenko YN, Tamizhmani K, Garbitt VM, Riggs DL, Brents LA, Roschke AV, et al. 2014. Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma. Leukemia 28: 1725-1735.
2. Buenrostro JD, Wu B, Chang HY, Greenleaf WJ. 2015. ATAC-seq: a method for assaying chromatin accessibility genome-wide. Curr Protoc Mol Biol 109: 21 29 21-29.
3. The Cancer Genome Atlas Network. 2015. Genomic classification of cutaneous melanoma. Cell 161: 1681-1696.
4. Chapuy B, McKeown MR, Lin CY, Monti S, Roemer MG, Qi J, Rahl PB, Sun HH, Yeda KT, Doench JG, et al. 2013. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell 24: 777-790.
5. Chipumuro E, Marco E, Christensen CL, Kwiatkowski N, Zhang T, Hatheway CM, Abraham BJ, Sharma B, Yeung C, Altabef A, et al. 2014. CDK7 inhibition suppresses super-enhancerlinked oncogenic transcription in MYCN-driven cancer. Cell 159: 1126-1139.
6. Gonzalez-Perez A, Jene-Sanz A, Lopez-Bigas N. 2013. The mutational landscape of chromatin regulatory factors across 4,623 tumor samples. Genome Biol 14: r106.
7. Groschel S, Sanders MA, Hoogenboezem R, de Wit E, Bouwman BA, Erpelinck C, van der Velden VH, Havermans M, Avellino R, van Lom K, et al. 2014. A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia. Cell 157: 369-381.
8. Heinz S, Romanoski CE, Benner C, Glass CK. 2015. The selection and function of cell type-specific enhancers. Nat Rev Mol Cell Biol 16: 144-154.
9. Hnisz D, Abraham BJ, Lee TI, Lau A, Saint-Andre V, Sigova AA, Hoke HA, Young RA. 2013. Super-enhancers in the control of cell identity and disease. Cell 155: 934-947.
10. Hnisz D, Schuijers J, Lin CY, Weintraub AS, Abraham BJ, Lee TI, Bradner JE, Young RA. 2015. Convergence of developmental and oncogenic signaling pathways at transcriptional super-enhancers. Mol Cell 58: 362-370.
11. Ho L, Crabtree GR. 2010. Chromatin remodelling during development. Nature 463: 474-484.
12. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Place C, et al. 2012. A landscape of driver mutations in melanoma. Cell 150: 251-263.
13. Hu G, Schones DE, Cui K, Ybarra R, Northrup D, Tang Q, Gattinoni L, Restifo NP, Huang S, Zhao K. 2011. Regulation of nucleosome landscape and transcription factor targeting at tissue-specific enhancers by BRG1. Genome Res 21: 1650-1658.
14. Iwafuchi-Doi M, Zaret KS. 2014. Pioneer transcription factors in cell reprogramming. Genes Dev 28: 2679-2692.
15. Kim J, Orkin SH. 2011. Embryonic stemcell-specific signatures in cancer: insights into genomic regulatory networks and implications for medicine. Genome Med 3: 75.
16. Kwiatkowski N, Zhang T, Rahl PB, Abraham BJ, Reddy J, Ficarro SB, Dastur A, Amzallag A, Ramaswamy S, Tesar B, et al. 2014. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature 511: 616-620.
17. Laurette P, Strub T, Koludrovic D, Keime C, Le Gras S, Seberg H, Van Otterloo E, Imrichova H, Siddaway R, Aerts S, et al. 2015. Transcription factor MITF and remodeller BRG1 define chromatin organisation at regulatory elements in melanoma cells. eLife doi: 10.7554/eLife.06857.
18. Lee JJ, Murphy GF, Lian CG. 2014. Melanoma epigenetics: novel mechanisms, markers, and medicines. Lab Invest 94: 822-838.
19. Loven J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, Bradner JE, Lee TI, Young RA. 2013. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 153: 320-334.
20. Mansour MR, Abraham BJ, Anders L, Berezovskaya A, Gutierrez A, Durbin AD, Etchin J, Lawton L, Sallan SE, Silverman LB, et al. 2014. Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science 346: 1373-1377.
21. Marzuka A, Huang L, Theodosakis N, Bosenberg M. 2015. Melanoma treatments: advances and mechanisms. J Cell Physiol 230: 2626-2633.
22. Masliah-Planchon J, Bieche I, Guinebretiere JM, Bourdeaut F, Delattre O. 2015. SWI/SNF chromatin remodeling and human malignancies. Annu Rev Pathol 10: 145-171.
23. Mayes K, Qiu Z, Alhazmi A, Landry JW. 2014. ATP-dependent chromatin remodeling complexes as novel targets for cancer therapy. Adv Cancer Res 121: 183-233.
24. Mehrotra A, Mehta G, Aras S, Trivedi A, de la Serna IL. 2014. SWI/SNF chromatin remodeling enzymes in melanocyte differentiation and melanoma. Crit Rev Eukaryot Gene Expr 24: 151-161.
25. Melton C, Reuter JA, Spacek DV, Snyder M. 2015. Recurrent somatic mutations in regulatory regions of human cancer genomes. Nat Genet 47: 710-716.
26. Min JN, Tian Y, Xiao Y, Wu L, Li L, Chang S. 2013. The mINO80 chromatin remodeling complex is required for efficient telomere replication and maintenance of genome stability. Cell Res 23: 1396-1413.
27. Morrison AJ, Shen X. 2009. Chromatin remodelling beyond transcription: the INO80 and SWR1 complexes. Nat Rev Mol Cell Biol 10: 373-384.
28. Northcott PA, Lee C, Zichner T, Stutz AM, Erkek S, Kawauchi D, Shih DJ, Hovestadt V, Zapatka M, Sturm D, et al. 2014. Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma. Nature 511: 428-434.
29. Piatti P, Zeilner A, Lusser A. 2011. ATP-dependent chromatin remodeling factors and their roles in affecting nucleosome fiber composition. Int J Mol Sci 12: 6544-6565.
30. Pott S, Lieb JD. 2015. What are super-enhancers? Nat Genet 47: 8-12.
31. Roberts CW, Orkin SH. 2004. The SWI/SNF complex—chromatin and cancer. Nat Rev Cancer 4: 133-142.
32. Shain AH, Pollack JR. 2013. The spectrum of SWI/SNF mutations, ubiquitous in human cancers. PLoS One 8: e55119.
33. Shutes A, Berzat AC, Cox AD, Der CJ. 2004. Atypical mechanism of regulation of the Wrch-1 Rho family small GTPase. Curr Biol 14: 2052-2056.
34. Tomayko MM, Reynolds CP. 1989. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 24: 148-154.
35. van denHurk K, Niessen HE, Veeck J, van denOord JJ, van Steensel MA, ZurHausen A, vanEngeland M, Winnepenninckx VJ.2012. Genetics and epigenetics of cutaneousmalignantmelanoma: a concert out of tune. Biochim Biophys Acta 1826: 89-102.
36. Walker BA, Wardell CP, Brioli A, Boyle E, Kaiser MF, Begum DB, Dahir NB, Johnson DC, Ross FM, Davies FE, et al. 2014. Translocations at 8q24 juxtaposeMYCwith genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients. Blood Cancer J 4: e191.
37. Wang L, Du Y, Ward JM, Shimbo T, Lackford B, Zheng X, Miao YL, Zhou B, Han L, Fargo DC, et al. 2014. INO80 facilitates pluripotency gene activation in embryonic stem cell self-renewal, reprogramming, and blastocyst development. Cell Stem Cell 14: 575-591.
38. Watanabe S, Peterson CL. 2010.The INO80 family of chromatinremodeling enzymes: regulators of histone variant dynamics. Cold Spring Harb Symp Quant Biol 75: 35-42.
39. Weinhold N, Jacobsen A, Schultz N, Sander C, Lee W. 2014. Genome-wide analysis of noncoding regulatory mutations in cancer. Nat Genet 46: 1160-1165.
40. West JA, Cook A, Alver BH, Stadtfeld M, Deaton AM, Hochedlinger K, Park PJ, Tolstorukov MY, Kingston RE. 2014. Nucleosomal occupancy changes locally over key regulatory regions during cell differentiation and reprogramming. Nat Commun 5: 4719.
41. Whyte WA, Orlando DA, Hnisz D, Abraham BJ, Lin CY, Kagey MH, Rahl PB, Lee TI, Young RA. 2013. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell 153: 307-319.